Navigation Links
VIVUS Provides Qnexa Regulatory Update
Date:1/9/2012

ical trial data; our response to questions and requests for additional information including additional pre-clinical or clinical studies from the European Medicines Agency, or EMA, and the Committee for Medicinal Products for Human Use, or CHMP, of the Marketing Authorization Application, or MAA, for Qnexa; the results of external studies to assess the teratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volat
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
2. VIVUS Reports Topline Findings From FORTRESS
3. VIVUS to Present at the Credit Suisse 2011 Healthcare Conference
4. VIVUS Resubmits Qnexa NDA to the FDA
5. VIVUS Provides Regulatory Update on QNEXA
6. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
7. VIVUS Announces $45.8 Million Registered Direct Offering of Common Stock
8. VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
9. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
10. VIVUS to Present at Three Upcoming Investor Conferences in March
11. VIVUS Provides Regulatory Update on QNEXA NDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... LOS ANGELES , Oct. 30, 2014 /PRNewswire/ ... biopharmaceutical research and development company specializing in oncology, ... technology and its lead drug candidate, aldoxorubicin.  The ... A New Approach," will be given by ... the Sarcoma Oncology Center and principal investigator of ...
(Date:10/30/2014)... October 30, 2014 ... beim Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie ... bei Säuglingen und Kleinkindern. Der bisher übliche ... Ernährung der Babys bzw. deren stillenden Mütter ... dass sich bei einer beträchtlichen Anzahl von ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... Selective Kinase Inhibitor Phase 1 Trial in ... 9, 2008 EntreMed, Inc.,(Nasdaq: ENMD ... the treatment of cancer and inflammatory diseases, ... 1, dose-escalation study for its,selective kinase inhibitor, ...
... 2008 The Association,for Professionals in Infection Control ... MT, MPH, of Albany, NY, has been named,the ... Award.,APIC presents the annual award to an infection ... of Carole DeMille, a pioneer,in infection control. The ...
Cached Medicine Technology:EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 2EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 3EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program 4New York Infection Prevention Expert Named Recipient of Carole DeMille Award 2
(Date:10/30/2014)... Florida (PRWEB) October 30, 2014 Timothy, ... visit to Pompano Beach firefighters, showing that you are ... , Timothy met firefighters Tracey and Carl at ... Galuppi’s Restaurant and the Pompano Beach Chamber of Commerce. ... the fire truck, letting Timothy wear his real fireman’s ...
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager ... help people save money through its innovative discount card ... drugs in the new health care system, the Paramount ... the relationship between consumers, businesses and the pharmacy industry. ... face today with medical costs is the rising price ...
(Date:10/30/2014)... Tara Haelle HealthDay ... -- More than 100 genes have been identified that ... report. And researchers say they are on their ... may contribute to the disorder. Autism spectrum disorders ... and social difficulties and repetitive behaviors. An estimated one ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, ... OB GYN in Melrose Park, IL and OB ... information about each of the care services and practice areas ... English and Spanish. The navigation of the website is ... provide Dr. Furlin’s patients with important information regarding his care ...
Breaking Medicine News(10 mins):Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... myocardial perfusion imaging is common, and in many patients is ... a study in the November 17 issue of JAMA ... is being presented at the American Heart Association,s annual meeting. ... years, but along with the potential benefits has come an ...
... the gradual accumulation in the brain of amyloid-beta peptide which is ... protein known as APP, which is found in three forms. Most ... disease does not distinguish between the different forms of the ... Chemistry , show that amyloid beta peptide is actually created mainly ...
... Reporter , SUNDAY, Nov. 14 (HealthDay News) -- Moderate drinking ... than not drinking at all, according to a trio of ... in Chicago. Not only did male coronary bypass ... was also boosted by a cocktail now and then. ...
... , SUNDAY, Nov. 14 (HealthDay News) -- ... the brain alter how they view themselves and others, ... aptitude for introspection, researchers say. Georgetown University Medical ... of the five scattered brain regions that comprise what,s ...
... of adult smokers dramatically decreased during the past three ... more quitting and fewer picking up the habit, according ... Sessions 2010. The Minnesota Heart Survey, a population-based, serial ... between 3,000 and 6,000 participants in each of its ...
... do not get enough sleep have higher levels of ... researchers have found. Data from a recent study ... the American Heart Association Scientific Sessions in Chicago by ... School of Medicine. The results come from surveying ...
Cached Medicine News:Health News:Common for patients to undergo multiple cardiac imaging tests, with high cumulative radiation dose 2Health News:Common for patients to undergo multiple cardiac imaging tests, with high cumulative radiation dose 3Health News:'Magic number' 695 opens up new areas for Alzheimer's research 2Health News:A Little Alcohol May Help the Heart: Studies 2Health News:A Little Alcohol May Help the Heart: Studies 3Health News:Brain Organizes Itself for Introspection as Children Age: Study 2Health News:Smoking among some adults dropped dramatically in past three decades 2Health News:Smoking among some adults dropped dramatically in past three decades 3Health News:Smoking among some adults dropped dramatically in past three decades 4Health News:Smoking among some adults dropped dramatically in past three decades 5Health News:Smoking among some adults dropped dramatically in past three decades 6Health News:Poor sleep quality increases inflammation, community study finds 2Health News:Poor sleep quality increases inflammation, community study finds 3
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
The revision knee system for severe joint deterioration with insufficient ligament support....
The major innovations in posterior stabilized (PS) knee design....
Medicine Products: